Tags

Type your tag names separated by a space and hit enter

Development and assessment of the Osteoporosis Index of Risk (OSIRIS) to facilitate selection of women for bone densitometry.
Gynecol Endocrinol. 2002 Jun; 16(3):245-50.GE

Abstract

A simple questionnaire would be useful to identify individuals most in need of bone mineral density (BMD) testing. We designed a new predictive model and risk assessment instrument based on an extensive review of the literature evaluating risk factors for osteoporosis, and tested its performance in a large cohort of postmenopausal women in whom BMD was measured by dual x-ray absorptiometry. In total, 1303 postmenopausal women from an outpatient osteoporosis clinic participated in this study. The Osteoporosis Index of Risk (OSIRIS) is based on four variables: age, body weight, current hormone replacement therapy use and history of previous low impact fracture. The sensitivity and specificity for an OSIRIS value of +1 were respectively 78.5% and 51.4%. The AUC under the ROC curve of OSIRIS was 0.71. Three categories were arbitrarily created using OSIRIS, with cutoff of +1 and -3. The low risk category (OSIRIS > +1) represented 41% of all women; only 7% of the women in this category had osteoporosis. The prevalence of osteoporosis was very high (66%) among the group at high risk (OSIRIS < -3 representing 15% of all women). The prevalence of osteoporosis was 39% in the intermediate risk group (-3 < OSIRIS < +1, 44% of all women). In conclusion, OSIRIS is a simple index based on four easy-to-collect variables from postmenopausal women, it shows a high degree of accuracy, and performed well for classifying the degree of risk of osteoporosis in western European women of Caucasian lineage. Based on this instrument it is possible to propose a strategy that would initiate treatment in women with very high risk, postpone BMD measurement in women with low risk and limit BMD measurement to women with intermediate risk of osteoporosis, this would spare more than 55% of the densitometry bill compared with a mass screening scenario.

Authors+Show Affiliations

WHO Collaborating Center for Public Health Aspects of Rheumatic Diseases, Liège, Belgium.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Validation Study

Language

eng

PubMed ID

12192897

Citation

Sedrine, W B., et al. "Development and Assessment of the Osteoporosis Index of Risk (OSIRIS) to Facilitate Selection of Women for Bone Densitometry." Gynecological Endocrinology : the Official Journal of the International Society of Gynecological Endocrinology, vol. 16, no. 3, 2002, pp. 245-50.
Sedrine WB, Chevallier T, Zegels B, et al. Development and assessment of the Osteoporosis Index of Risk (OSIRIS) to facilitate selection of women for bone densitometry. Gynecol Endocrinol. 2002;16(3):245-50.
Sedrine, W. B., Chevallier, T., Zegels, B., Kvasz, A., Micheletti, M. C., Gelas, B., & Reginster, J. Y. (2002). Development and assessment of the Osteoporosis Index of Risk (OSIRIS) to facilitate selection of women for bone densitometry. Gynecological Endocrinology : the Official Journal of the International Society of Gynecological Endocrinology, 16(3), 245-50.
Sedrine WB, et al. Development and Assessment of the Osteoporosis Index of Risk (OSIRIS) to Facilitate Selection of Women for Bone Densitometry. Gynecol Endocrinol. 2002;16(3):245-50. PubMed PMID: 12192897.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Development and assessment of the Osteoporosis Index of Risk (OSIRIS) to facilitate selection of women for bone densitometry. AU - Sedrine,W B, AU - Chevallier,T, AU - Zegels,B, AU - Kvasz,A, AU - Micheletti,M C, AU - Gelas,B, AU - Reginster,J Y, PY - 2002/8/24/pubmed PY - 2003/1/15/medline PY - 2002/8/24/entrez SP - 245 EP - 50 JF - Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology JO - Gynecol Endocrinol VL - 16 IS - 3 N2 - A simple questionnaire would be useful to identify individuals most in need of bone mineral density (BMD) testing. We designed a new predictive model and risk assessment instrument based on an extensive review of the literature evaluating risk factors for osteoporosis, and tested its performance in a large cohort of postmenopausal women in whom BMD was measured by dual x-ray absorptiometry. In total, 1303 postmenopausal women from an outpatient osteoporosis clinic participated in this study. The Osteoporosis Index of Risk (OSIRIS) is based on four variables: age, body weight, current hormone replacement therapy use and history of previous low impact fracture. The sensitivity and specificity for an OSIRIS value of +1 were respectively 78.5% and 51.4%. The AUC under the ROC curve of OSIRIS was 0.71. Three categories were arbitrarily created using OSIRIS, with cutoff of +1 and -3. The low risk category (OSIRIS > +1) represented 41% of all women; only 7% of the women in this category had osteoporosis. The prevalence of osteoporosis was very high (66%) among the group at high risk (OSIRIS < -3 representing 15% of all women). The prevalence of osteoporosis was 39% in the intermediate risk group (-3 < OSIRIS < +1, 44% of all women). In conclusion, OSIRIS is a simple index based on four easy-to-collect variables from postmenopausal women, it shows a high degree of accuracy, and performed well for classifying the degree of risk of osteoporosis in western European women of Caucasian lineage. Based on this instrument it is possible to propose a strategy that would initiate treatment in women with very high risk, postpone BMD measurement in women with low risk and limit BMD measurement to women with intermediate risk of osteoporosis, this would spare more than 55% of the densitometry bill compared with a mass screening scenario. SN - 0951-3590 UR - https://www.unboundmedicine.com/medline/citation/12192897/Development_and_assessment_of_the_Osteoporosis_Index_of_Risk__OSIRIS__to_facilitate_selection_of_women_for_bone_densitometry_ L2 - http://www.diseaseinfosearch.org/result/9059 DB - PRIME DP - Unbound Medicine ER -